Fertility warning
This medicine may affect fertility.
Leaflet PEGASYS 135mcg / 0.5ml solution for injection in pre-filled syringe
- Product code:
- W52673003
- Quantity:
- 1
- Indicated for:
- viral infections; multiple sclerosis; cancer
- Route of administration:
- injectable
- Substance:
- peginterferon alfa-2A (antineoplastic agent)
- ATC
- L03AB11 — Antineoplastic and immunomodulating agents | Immunostimulants | Immunostimulants | Interferons
Precautions:
Dose adjustment in hepatic impairment
Dose adjustment may be needed in liver disease.
Cytotoxic / special handling
Handle with special care.
Contraception required
Effective contraception is required during treatment.
Contraindicated during breastfeeding
Do not use this medicine while breastfeeding.
Contraindicated during pregnancy
Do not use this medicine during pregnancy.
Hepatotoxicity
This medicine may affect the liver.
Major drug interactions
This medicine may have important interactions with other medicines.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Additional monitoring
This medicine is subject to additional monitoring.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Severe skin reactions
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Peginterferon alfa-2a is an immunomodulatory agent used in the treatment of chronic hepatitis B and C. It works by stimulating the body's immune response to fight viral infections.
The medication is administered subcutaneously, as directed by a doctor, usually once a week. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the response to therapy.
Patients should be aware of potential side effects, such as fatigue, fever, or flu-like symptoms. It is important to inform the doctor of any unusual symptoms.
Common side effects include fatigue, fever, and flu-like symptoms. In rare cases, severe reactions such as depression or hematologic disorders may occur. Patients should be informed of these risks before use.
The medication is administered subcutaneously, as directed by a doctor, usually once a week. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the response to therapy.
Patients should be aware of potential side effects, such as fatigue, fever, or flu-like symptoms. It is important to inform the doctor of any unusual symptoms.
Common side effects include fatigue, fever, and flu-like symptoms. In rare cases, severe reactions such as depression or hematologic disorders may occur. Patients should be informed of these risks before use.
General data about PEGASYS 135mcg / 0.5ml
- Substance:
- peginterferon alfa-2A
- Date of latest medicines list:
- 01-04-2014
- Product code:
- W52673003
- Concentration:
- 135mcg / 0.5ml
- Pharmaceutical form:
- solution for injection in pre-filled syringe
- Quantity:
- 1
- Product type:
- Original
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for peginterferon alfa-2A
Concentrations available for peginterferon alfa-2A
- 135mcg/0.5ml
- 135mcg/ml
- 180mcg/0.5ml
- 180mcg/ml